DATATRAK's CRO Connect program is a non-exclusive enterprise agreement and accreditation relationship that empowers CROs to design and deploy their own EDC trials using DATATRAK's unified eClinical platform. As a CRO Connect partner, Diverse Lynx will be able to offer eClinical services to its clients through a standardize offering.
"We are pleased to add Diverse Lynx to our CRO Connect program," stated Dr. Jeffrey A. Green, Chief Executive Officer of DATATRAK International, Inc. "Collaboratively, this program allows Diverse Lynx to offer our standardized eClinical platform to best serve their sponsor's clinical trial needs. Our CRO model allows them to offer very predictable research and development costs while eliminating wasted time involved with negotiation and contracting under the trial-by-trial mode. This model has tremendous advantages to DATATRAK and Diverse Lynx with solid visibility of revenues over a multi-year period of time combined with a greatly diminished cost of sales."
"Our partnership with DATATRAK International is a big step towards offering absolute clinical data management services for data capture, processing, analysis and management services in the most cost effective approach with the highest quality. We now have a strong data management infrastructure to match our organization in Europe, Japan and Asian countries, covering over 20 countries," said Shubhendra Varma, President of Diverse Lynx. "At Diverse Lynx, we take this partnership several steps further by emphasizing long-term, value-added relationships and a commitment to understand our sponsors' business needs."

About DATATRAK International:
DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ stock Market under the ticker symbol "DATA". 

Visit the DATATRAK International, Inc. web site at www.datatrak.net .

About Diverse Lynx:
Diverse Lynx is a rapidly growing Information Technology and, Clinical Research and Data Management Company focused on providing contract research services to develop drugs and clinical trials to leading pharmaceutical, Biotech companies and government agencies globally. Its IT division provides a litany of diverse services that include staff supplementation through workforce contracting, e-business consulting, web-based applications, Client Server Applications, network solutions and other in-house and offshore software developments. Its Clinical Trial & Data Management division offers clinical research support to the global pharmaceutical industry and supports sponsors in their clinical trial management, pharmacovigilance and safety risk management, data management and regulatory affairs in the area of Oncology, Neurology, Psychiatry, Cardiology, Nephrology, Infectious Diseases and therapeutics vaccines. Headquartered out of New Jersey, USA with an office in India, Diverse Lynx has collaboration throughout Europe as well as in Japan and Russia. For more information please visit Diverse Lynx website at www.diverselynx.com .

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement.